Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Enanta Pharmaceuticals Inc shares valued at $18,401 were sold by Kieffer Tara Lynn on Dec 06 ’24. At $8.06 per share, Kieffer Tara Lynn sold 2,283 shares. The insider’s holdings dropped to 29,305 shares worth approximately $0.17 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Luu Brendan sold 2,283 shares, netting a total of over 18,401 in proceeds. Following the sale of shares at $8.06 each, the insider now holds 36,047 shares.
Before that, Rottinghaus Scott T. had sold 866 shares from its account. In a trade valued at $6,980, the Chief Medical Officer traded Enanta Pharmaceuticals Inc shares for $8.06 each. Upon closing the transaction, the insider’s holdings decreased to 866 shares, worth approximately $0.1 million.
As published in a research note from JP Morgan on August 09, 2023, Enanta Pharmaceuticals Inc [ENTA] has been rated down from a Neutral to an Underweight and the price target has been revised to $14. Analysts at Jefferies downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in early August. As of December 09, 2022, H.C. Wainwright has initiated its “Buy” rating for ENTA. Earlier on July 06, 2022, Evercore ISI upgraded its rating. Their new recommendation was “an Outperform” for ENTA stock which previously was a “an In-line”.
Analyzing ENTA Stock Performance
During the last five days, there has been a drop of approximately -16.43%. Over the course of the year, Enanta Pharmaceuticals Inc shares have dropped approximately -37.83%. Shares of the company reached a 52-week high of $17.80 on 04/01/24 and a 52-week low of $5.70 on 12/18/24. A 50-day SMA is recorded $9.96, while a 200-day SMA reached $12.53. Nevertheless, trading volume fell to 0.65 million shares from 0.35 million shares the previous day.
Support And Resistance Levels for Enanta Pharmaceuticals Inc (ENTA)
According to the 24-hour chart, there is a support level at 5.67, which, if violated, would cause prices to drop to 5.49. In the upper region, resistance lies at 6.06. The next price resistance is at 6.27. RSI (Relative Strength Index) is 24.38 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.45, which suggests the price will decrease in the coming days. Percent R is at 96.14%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
